AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35189943
Drug: TLC599 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC599 12 mg
Trial: 35189943
Drug: TLC599 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC599 18 mg
Trial: 34496979
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) 50 mg/week plus Methotrexate (MTX)
Trial: 34613513
Drug: Osmotic Release
RxNorm normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Osmotic Release Oral System (OROS) Methylphenidate (MPH)
Trial: 32066605
Drug: Brief support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief support for self-management of weight during child immunisation appointments, including weekly self-weighing and use of an online weight management programme.
Trial: 616850836
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg genistein daily for 3-6 weeks before prostatectomy
Trial: 616850836
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules daily for 3-6 weeks before prostatectomy
Trial: 36382431
Drug: Rectal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rectal midazolam (0.3 mg/kg, max 15 mg)
Trial: 36335684
Drug: Prednisolone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (5 mg/day)
Trial: 35241135
Drug: Neostigmine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (1 mg every 12 hours, increased to every 8 hours or every 6 hours depending on response)
Trial: 36418088
Drug: Suprascapular nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprascapular nerve block (SSNB) with glenohumeral joint (GHJ) injection and physiotherapy
Trial: 36418088
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with glenohumeral joint (GHJ) injection and physiotherapy
Trial: 38965031
Drug: High-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity statin therapy
Trial: 34585554
Drug: LDL-C <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C < 70 mg/dl
Trial: 34585554
Drug: ACEI /
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI / ARB therapy
Trial: 34330312
Drug: Ellagic acid
RxNorm normalized name: Ellagic acid
DrugBank: Ellagic acid (DB08846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ellagic acid (200 mg per day)
Trial: 35255819
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy plus S. boulardii (Group S)
Trial: 35255819
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy plus L. reuteri (Group P)
Trial: 36201678
Drug: Informational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Informational intervention emphasizing evidence-based harm reduction and treatment programs
Trial: 35691460
Drug: PBRM (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBRM (15 mg/kg orally by gavage)
Trial: 32075571
Drug: Primary intraventricular
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary intraventricular hemorrhage patients (combined treatment groups)
Trial: 34407025
Drug: Integrated yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated yoga therapy (asanas and pranayama) from 18 to 22 weeks of gestation until delivery
Trial: 32759258
Drug: Nintedanib 150
RxNorm normalized name: nintedanib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 150 mg two times per day
Trial: 35180569
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care program (medication review, health education, adherence aids, seizure registration, therapeutic drug monitoring)
Trial: 35180569
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care program vs. Usual care
Trial: 34976813
Drug: Single-agent sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent sodium cantharidinate (SCA)
Trial: 34976813
Drug: Single-agent docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-agent docetaxel (DOX)
Trial: 34976813
Drug: Docetaxel/sodium cantharidinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel/sodium cantharidinate combination (CON)
Trial: 34976813
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (single-agent SCA and single-agent DOX)
Trial: 35844809
Drug: Sublingual sufentanil
RxNorm normalized name: sufentanil Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual sufentanil 30 mcg
Trial: 35844809
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl 50 mcg
Trial: 32756180
Drug: High-volume hemofiltration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume hemofiltration (HVHF), 24 hours continuous treatment, n = 21
Trial: 35969887
Drug: Low-dose 17β
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose 17β estradiol (n = 72)
Trial: 32103495
Drug: ω‐3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months) after periodontal debridement (TG1)
Trial: 32103495
Drug: ω‐3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months) before periodontal debridement (TG2)
Trial: 36106652
Drug: Insulin icodec
RxNorm normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin icodec (once-weekly basal insulin)
Trial: 36106652
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine U100 or U300 or insulin degludec (comparator treatments)
Trial: 36106652
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine U100 or U300 or insulin degludec
Trial: 33464335
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase plus endovascular thrombectomy
Trial: 32383767
Drug: Oral probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral probiotic capsules containing Lactobacillus paracasei LPC‐S01 (24 billion CFU)
Trial: 32712606
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (4 sessions over 4-6 weeks)
Trial: 36482786
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg acetaminophen
Trial: 36482786
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg acetaminophen
Trial: 32469182
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (6.4 mg/kg every 3 weeks)
Trial: 32469182
Drug: Chemotherapy (physician's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (physician's choice, 55 received irinotecan and 7 paclitaxel)
Trial: 35272017
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (100,000 IU monthly)
Trial: 37549923
Drug: 13-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-valent pneumococcal conjugate vaccine
Trial: 32620335
Drug: Probiotics (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (1 × 10^9 CFU/day, 2 capsules, tid) for 2 months
Trial: 32102507
Drug: Serological noninvasive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serological noninvasive screening and treatment for atrophic gastritis
Trial: 36244364
Drug: Risdiplam (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risdiplam (0.2 mg/kg for infants 5 months to 2 years, adjusted for younger infants)
Trial: 32045540
Drug: New clinical
RxNorm normalized name: octinoxate 75 mg in 1 g / oxybenzone 40 mg in 1 g / avobenzone 20 mg in 1 g TOPICAL CREAM [Anew Clinical Absolute Even Spot Correcting Hand]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New clinical V̇O2 peak equation from 6MWT: V̇O2 peak (mL.kg‐1.min‐1) = (‐0.283*age(years)) ‐ (0.099*weight(kg)) + (0.071*6MWD(meters)) ‐(0.135*HR end(bpm)) + 22.789
Trial: 32045540
Drug: New disease-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New disease-specific V̇O2 peak equation from 6MWT: V̇O2 peak (mL.kg‐1.min‐1) = (‐0.236*age(years)) ‐ (0.094*weight(kg)) ‐(0.120*HR end(bpm)) + (0.067*6MWD(meters)) + (0.065*MVLPA(min/day)) ‐ (0.204*DT(years)) + 25.145
Trial: 34275774
Drug: Drug holiday
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug holiday from 1 month before to 3 months after surgical tooth extraction
Trial: 34275774
Drug: Drug continuation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug continuation
Trial: 35893914
Drug: Oligomeric hyperproteic
RxNorm normalized name: procyanidolic oligomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligomeric hyperproteic normocaloric (OHN) supplement
Trial: 35893914
Drug: Immunonutritional (IN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunonutritional (IN) supplement
Trial: 35791877
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg of caffeine during baseline night (BN)
Trial: 35791877
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg of caffeine during total sleep deprivation (TSD)
Trial: 35791877
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg of caffeine during BN
Trial: 35791877
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg of caffeine during TSD
Trial: 35015903
Drug: Subcutaneous methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous methotrexate (MTX)
Trial: 32078436
Drug: Cocoa beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa beverage (15 g of cocoa and 75 mg of epicatechin daily)
Trial: 36194164
Drug: Everolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (10 mg, oral daily for a maximum of 1 year)
Trial: 33812488
Drug: More-delayed strategy
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More-delayed strategy (RRT initiation postponed until mandatory indication or blood urea nitrogen concentration reached 140 mg/dL)
Trial: 33285624
Drug: Focused shock
RxNorm normalized name: house dust allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused shock wave therapy (FSWT)
Trial: 35379064
Drug: Ticagrelor (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (90 mg twice daily for 2 weeks)
Trial: 32196749
Drug: ABP 959
RxNorm normalized name: ABPC
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ABP 959 (300 mg IV infusion)
Trial: 35400328
Drug: Sacubitril/valsartan (97/103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan (97/103 mg once or twice daily)
Trial: 35400328
Drug: Telmisartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (40 mg once or twice daily)
Trial: 38267024
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant therapy (OAC)
Trial: 33509129
Drug: Oral dydrogesterone
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dydrogesterone (10 mg three times per day)
Trial: 32744483
Drug: Standard pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmacological treatment and usual physical or psychological activities
Trial: 35870990
Drug: S(+)‐ketamine hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)‐ketamine hydrochloride injection
Trial: 35870990
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy without S(+)‐ketamine
Trial: 35460601
Drug: Ritonavir-boosted darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir-boosted darunavir (800 mg of darunavir plus 100 mg of ritonavir once daily)
Trial: 35460601
Drug: Tenofovir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir (300 mg once daily) plus lamivudine (300 mg once daily)
Trial: 35460601
Drug: Zidovudine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (300 mg twice daily) plus lamivudine (150 mg twice daily)
Trial: 32756135
Drug: Extracorporeal shock-wave
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock-wave therapy (ESWT) - 3 sessions on the first, 14th, and 28th days
Trial: 32756135
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone - 30 mg daily for 2 weeks, then 15 mg daily for another 2 weeks
Trial: 35604613
Drug: Bilateral erector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral erector spinae plane block using 20 ml of 0.375% ropivacaine on each side (ESPB group, n = 42)
Trial: 32331018
Drug: Valbenazine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valbenazine (40 or 80 mg)
Trial: 33747831
Drug: Digital educational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital educational support group administered through WhatsApp Messenger
Trial: 33201347
Drug: Fluconazole 400
RxNorm normalized name: fluconazole 400 MG in 200 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 400 mg daily for 8 days
Trial: 35218405
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg BUP (BUP16)
Trial: 33232628
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: planned, structured follow-up telephone contact with the research nurse the day after discharge and then once weekly for 6 weeks
Trial: 32611505
Drug: Afatinib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (30 mg or 40 mg orally daily)
Trial: 32611505
Drug: Chemotherapy (pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 or carboplatin AUC 5 or 6 every 3 weeks × 4 cycles, followed by pemetrexed 500 mg/m2 every 3 weeks)
Trial: 33530006
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus a brief educational video on safe storage and disposal practices of unused opioid pills
Trial: 35897080
Drug: Lidocaine-only injection
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine-only injection
Trial: 34353223
Drug: Peri/postmenopausal women
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri/postmenopausal women with menopausal hormone therapy (MHT)
Trial: 35080109
Drug: 0.125 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg/kg IV pimobendan
Trial: 35080109
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg IV pimobendan
Trial: 35080109
Drug: IV pimobendan
RxNorm normalized name: Pimobendan
DrugBank: Pimobendan (DB11450)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV pimobendan (both doses)
Trial: 32390550
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment in patients with prior OAC
Trial: 32390550
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment in patients without prior OAC
Trial: 33417146
Drug: Mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 50 mg once daily for 4 weeks (Group A; n = 32)
Trial: 36473425
Drug: ARA 100
RxNorm normalized name: Seysara 100mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARA 100 mg/kg and DHA 50 mg/kg
Trial: 32785940
Drug: Immunotherapy (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (single agents and combinations)
Trial: 36145087
Drug: Wagyu‐Cross beef
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wagyu‐Cross beef (120 g consumed four days/week for four weeks)
Trial: 36145087
Drug: Commercial beef
RxNorm normalized name: Beef
DrugBank: Beef (DB10509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial beef (120 g consumed four days/week for four weeks)
Trial: 35429946
Drug: Caffeine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (20 mg/kg initial dose, then 10 mg/kg daily maintenance)
Trial: 34814657
Drug: Mud plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud plus bath therapy (group 1)
Trial: 32891286
Drug: Cupping therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cupping therapy at -0.02 mpa
Trial: 32891286
Drug: Cupping therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cupping therapy at -0.03 mpa
Trial: 32891286
Drug: Cupping therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cupping therapy at -0.05 mpa
Trial: 35124808
Drug: Preoperative high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative high-dose dexamethasone (1 mg/kg)
Trial: 35523502
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT scan (LDCT)
Trial: 34934009
Drug: Downward titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Downward titration of the level of pressure support (PSV)
Trial: 34197338
Drug: Dog-Assisted Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dog-Assisted Therapy (DAT)
Trial: 34298029
Drug: Minocycline 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 200 mg with Oxycodone 40 mg
Trial: 34298029
Drug: Minocycline 100
RxNorm normalized name: minocycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg with Oxycodone 40 mg
Trial: 34298029
Drug: Oxycodone 40
RxNorm normalized name: ibuprofen-oxycodone 400 mg-5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 40 mg alone
Trial: 35129789
Drug: Medication reconciliation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reconciliation and medication review conducted by study pharmacists in addition to standard care
Trial: 32950693
Drug: Defibrotide (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (6.25 mg/kg every 6 hours, administered as a 2-hour i.v. infusion, for a minimum of 21 days or until resolution of VOD/SOS signs and symptoms)
Trial: 32950693
Drug: Defibrotide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (25 mg/kg/day in phase 2 study)
Trial: 36197920
Drug: modified directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified directly observed therapy (mDOT)
Trial: 36197920
Drug: standard individual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard individual therapy (SIT)
Trial: 36197920
Drug: groups therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: groups therapy (GT)
Trial: 34611892
Drug: Intensified therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified therapy with aspirin 100 mg once daily in combination with clopidogrel 150 mg once daily
Trial: 34611892
Drug: Intensified therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified therapy with aspirin 100 mg once daily in combination with clopidogrel 75 mg once daily plus cilostazol 100 mg twice daily
Trial: 34611892
Drug: Intensified therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified therapy with aspirin 100 mg once daily in combination with ticagrelor 90 mg twice daily
Trial: 34611892
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy with clopidogrel 75 mg once daily (STD)
Trial: 34611892
Drug: Intensified therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified therapy (all combinations)
Trial: 33849821
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (CC and HMG)
Trial: 32138563
Drug: β-Alanine (BA)
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-Alanine (BA) supplementation (12 g·day‐1 for 14 days)
Trial: 35377934
Drug: PDL injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDL injection and alternative palatal infiltration